Multiple sclerosis and related disorders · 2026
Antinuclear antibodies, apoptotic factors sFas and sFasL, and chemokines CXCL8, CXCL10, and CCL20 as prognostic biomarkers in multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sremec Josip, Košćak Lukač Jelena, Raifi Zurap, Bačić Baronica Koraljka, Tomić Sremec Nada, Ruška Berislav, Tomasović Sanja
Аннотация
BACKGROUND: Despite a significant advance in multiple sclerosis (MS) treatment, the lack of reliable and easily available prognostic biomarkers, even with serum NfL and GFAP now available, is more exposed than ever, as they would enable tailoring the therapeutic approach to an individual. Since we earlier demonstrated a link between antinuclear antibodies (ANA) and soluble apoptotic factors sFas and sFasL, as well as between CXCL8 and CXCL10 chemokine levels and MS relapses, these analytes were deemed suitable for longitudinal assessment in this sense.
MATERIALS AND METHODS: Forty-two people with MS (pwMS) were followed for a median of 68 months, and their initial ANA status, as well as concentrations of sFas, sFasL, CXCL8, CXCL10, and CCL20 were assessed in relation to relapses, disability accrual, and therapy usage during follow up.
RESULTS: There are fewer pwMS who relapsed amongst those with positive ANA. These subjects had longer relapse-free survival, and lower hazard and odds ratio for relapse compared to ANA-negative pwMS. This was even more pronounced in pwMS with low initial sFasL concentrations, which correlated with higher annualized relapse rate, especially in ANA-negative subjects. CXCL8 concentrations point to a potentially promising sensitivity and specificity for future disability worsening.
CONCLUSION: ANA presence, alone or in conjunction with sFasL concentrations, could potentially be developed into a prognostic biomarker in pwMS regarding disease activity, while same is true for CXCL8 regarding disability accrual. However, it should be noted that these are exploratory findings requiring external validation. Further studies, especially those with follow-up started at the time of diagnosis, are warranted.
MATERIALS AND METHODS: Forty-two people with MS (pwMS) were followed for a median of 68 months, and their initial ANA status, as well as concentrations of sFas, sFasL, CXCL8, CXCL10, and CCL20 were assessed in relation to relapses, disability accrual, and therapy usage during follow up.
RESULTS: There are fewer pwMS who relapsed amongst those with positive ANA. These subjects had longer relapse-free survival, and lower hazard and odds ratio for relapse compared to ANA-negative pwMS. This was even more pronounced in pwMS with low initial sFasL concentrations, which correlated with higher annualized relapse rate, especially in ANA-negative subjects. CXCL8 concentrations point to a potentially promising sensitivity and specificity for future disability worsening.
CONCLUSION: ANA presence, alone or in conjunction with sFasL concentrations, could potentially be developed into a prognostic biomarker in pwMS regarding disease activity, while same is true for CXCL8 regarding disability accrual. However, it should be noted that these are exploratory findings requiring external validation. Further studies, especially those with follow-up started at the time of diagnosis, are warranted.